Insmed targets $405M-$425M ARIKAYCE revenue for 2025 while advancing brensocatib and TPIP ...
Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, ...
Insider Monkey23 天
15 Best Biotech Stocks to Buy According to Billionaires
Its leading therapy, ARIKAYCE (amikacin liposome inhalation suspension), is used to treat Mycobacterium avium complex (MAC) lung disease in patients with limited treatment options. The company is ...